NCT07720817 Ultrasound Guided Retrolaminar Block Versus Transverse Abdominis Plane Block in Laparoscopic Upper Abdominal Surgeries
| NCT ID | NCT07720817 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Mansoura University |
| Condition | Retrolaminar Block |
| Study Type | INTERVENTIONAL |
| Enrollment | 164 participants |
| Start Date | 2026-07-01 |
| Primary Completion | 2027-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 164 participants in total. It began in 2026-07-01 with a primary completion date of 2027-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This study aims to compare and evaluate the safety and efficacy of ultrasound guided retrolaminar block versus transverse abdominis plane block in laparoscopic upper abdominal surgeries. Both RLB and TAP blockade are hypothesized to reduce analgesic consumption, manage pain effectively and minimize side effects but their comparative effectiveness has not yet to be thoroughly explored.
Eligibility Criteria
Inclusion Criteria: * Age between 21 and 65 years. * American Society of Anesthesiologists (ASA) physical status I or II. * Body mass index (BMI) less than 30 kg/m². * Scheduled for elective laparoscopic upper abdominal surgery under general anesthesia. Exclusion Criteria: * Refusal to participate in the study. * Known allergy or hypersensitivity to any of the study drugs. * Infection at the planned block insertion site. * Severe uncontrolled cardiac, renal, hepatic, neurological, or respiratory disease. * Pre-existing chronic pain. * Immunodeficiency. * Coagulation abnormalities, anticoagulant therapy, or platelet count less than 80,000/µL. * Emergency surgery.
Contact & Investigator
hatem saber mohamed ali, Professor
STUDY CHAIR
Faculty of Medicine, Mansoura University
Frequently Asked Questions
Who can join the NCT07720817 clinical trial?
This trial is open to participants of all sexes, aged 21 Years or older, up to 65 Years, studying Retrolaminar Block. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07720817 currently recruiting?
Yes, NCT07720817 is actively recruiting participants. Contact the research team at melnaggar789@gmail.com for enrollment information.
Where is the NCT07720817 trial being conducted?
This trial is being conducted at Al Mansurah, Egypt.
Who is sponsoring the NCT07720817 clinical trial?
NCT07720817 is sponsored by Mansoura University. The principal investigator is hatem saber mohamed ali, Professor at Faculty of Medicine, Mansoura University. The trial plans to enroll 164 participants.